• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 22, 2017

View Archived Issues

In the clinic

Ironwood Pharmaceuticals Inc., of Cambridge, Mass., said it started STRONG-SCD, a phase II trial evaluating once-daily IW-1701, an orally administered soluble guanylate cyclase (sGC) stimulator, in patients with sickle cell disease. IW-1701 has been shown to improve nitric oxide signaling in nonclinical studies, and is being investigated for its potential to treat multiple aspects of sickle cell disease pathophysiology, including red blood cell sickling, decreased blood flow and vascular inflammation. Read More

Other news to note

Mesoblast Ltd., of Melbourne, Australia, said the FDA granted regenerative medicine advanced therapy designation to its mesenchymal precursor cell (MPC) therapy for the treatment of heart failure patients with left ventricular systolic dysfunction and left ventricular assist devices (LVADs). Read More

Financings

Sensorion SA, of Montpellier, France, said it carried out a capital increase of €1.6 million reserved to Cochlear Investment Ltd., of Sydney. Read More

Holiday notice

BioWorld's offices will be closed in observance of Christmas. Read More

Mavupharma raises $20M series A for STING therapies

Mavupharma Inc., a new company developing therapies for cancer and infectious diseases, recently secured a $20 million series A financing led by Frazier Healthcare Partners, joined by Alpine Bioventures. Read More

An unconventional model: Caywon taking advantage of Crowd Machine platform

HONG KONG – Caywon Pharmaceutical Group Ltd. is using Crowd Machine technology to become one of the first companies in China to specialize in decentralizing the pharmaceuticals development process. Read More

Flx adds GV in $60M series C, moves CCR4 antagonist to clinic

Flx Bio Inc. completed a $60 million series C, adding GV (formerly Google Ventures) and several undisclosed investors to its syndicate. Existing investors, including the Column Group, Kleiner Perkins, Topspin Partners and Celgene Corp., also joined the round. Read More

Tax reform chops orphan drug credit; device tax persists

Tax reform is headed for the Oval Office for a signature, a bill that provides a mixed bag for the life sciences. While the corporate tax rate will fall by double-digit percentage in the years ahead, the orphan drug tax credit is cut in half and the 2.3 percent medical device tax is set to come back into play as of Jan. 1, 2018. Read More

Regulatory front

The Center for Drug Evaluation and Research at the FDA said it will require a new set of warnings for gadolinium-based contrast agents used in MRI procedures, despite that an FDA advisory committee indicated no adverse effects in patients with normal kidney function. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe